Lisette Helene Deddens1, Peter A. Jarzyna2, Arjan W. Griffioen3, Zahi A. Fayad2, Rick Michiel Dijkhuizen1, Willem JM Mulder2
1Image Sciences Institute, University Medical Center Utrecht, Utrecht, Netherlands; 2Imaging Science Laboratories, Mount Sinai School of Medicine, New York, United States; 3Angiogenesis Laboratory Amsterdam, VU Medical Center, Amsterdam, Netherlands
Nanoemulsions represent an attractive delivery platform for hydrophobic compounds since they improve their bioavailability and make their intravenous administration possible. This abstract demonstrates that the nanoemulsion platform, developed for passive delivery of hydrophobic compounds to tumor tissue, is also very suitable for targeted applications. Data show the applicability of αvβ3-specific RGD nanoemulsions in targeting tumor angiogenesis visualized by MRI, fluorescence microscopy and immunohistochemistry.